Month: May 2022

– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease Medicine; U.S. Launch Underway – – PYRUKYND® Pivotal Studies in Thalassemia and Sickle Cell Disease Open and Enrolling; Start-Up Activities Ongoing for Pediatric PK Deficiency Program – – Completed Healthy Volunteer Cohorts and Initiated Sickle Cell Disease Cohort of AG-946 Phase 1 Study; On Track to Initiate Phase 2a Study in Myelodysplastic Syndrome by Year-End – – Cash, Cash Equivalents and Marketable Securities $1.2 Billion as of March 31, 2022 – CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “It has been a very productive first quarter for Arvinas, as we prepare to initiate three planned pivotal clinical studies in the second half of 2022 for our two lead programs – ARV-471 in metastatic breast cancer and bavdegalutamide in molecularly defined metastatic castration-resistant prostate cancer,” said John Houston, Ph.D., chief executive officer and president at Arvinas. “We have a unique opportunity to bring these two programs into late-stage development at the same time, demonstrating the potential of our PROTAC® platform to...

– Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 – – Target enrollment achieved in SELECT trial of vopratelimab in combination with pimivalimab; data expected in 2H2022 – – Ended the quarter with $186.4 million in cash, cash equivalents and investments – – Company to host conference call and webcast today at 8:00 AM ET – CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate...

HOLMDEL, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Vonage Holdings Corp. (Nasdaq: VG), a global leader in cloud communications helping businesses accelerate their digital transformation, today announced results for the quarter ended March 31, 2022. First Quarter 2022 Highlights:Consolidated revenue of $359 million, an increase of 8% year-over-yearConsumer revenue of $62 million, a decrease of 19% year-over-year Vonage Communications Platform (VCP) revenue of $296 million, an increase of 16% year-over-yearVCP Service revenue of $284 million, an increase of 18% year-over-yearAPI revenue of $162 million, an increase of 28% year-over-year Unified Communications & Contact Center Service revenue of $123 million, an increase of 7% year-over-yearConsolidated Net Loss of $17 million, a decrease of $17 million from the prior...

CEDAR RAPIDS, Iowa, May 05, 2022 (GLOBE NEWSWIRE) — United Fire Group, Inc. (Nasdaq: UFCS) Consolidated Financial Results – Highlights(1):Three Months Ended March 31, 2022  Net income per diluted share $1.12  Adjusted operating income(2)per diluted share $1.13  Net investment gains (losses) per diluted share $(0.01 )GAAP combined ratio   89.5 %Book value per share $33.27  Return on equity(3)   13.2 %United Fire Group, Inc. (the “Company” or “UFG”) (Nasdaq: UFCS) today reported consolidated net income, including net investment losses and changes in the fair value of equity securities, of $28.3 million ($1.12 per diluted share) for the three-month period ended March 31, 2022 (the “first quarter of 2022”), compared to consolidated net income of $18.7 million ($0.74...

MONACO, May 05, 2022 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the first quarter ended March 31, 2022 (“Q1 2022”). I. RECORD PROFITABILITY IN A FIRST QUARTER SINCE NYSE LISTINGQ1 2022 Net Income available to common stockholders of $115.4 million ($0.93 per share) vs $60.5 million ($0.49 per share) in Q1 2021. Q1 2022 Adjusted Net Income available to common stockholders1 of $104.5 million ($0.84 per share) vs $38.0 million ($0.31 per share) in Q1 2021. Q1 2022 liquidity of $644 million2 vs $240 million in Q1 2021.II. NEW CHARTER ARRANGEMENTS3 AND FULLY EMPLOYED CONTAINERSHIP FLEET FOR THE YEAR AHEADContainership fleet fully employed for the remainder of 2022. More than 90% of the containership fleet4 is fixed for 2023. Entered into a total...

17% net sales growth offset inflationary pressures contributing to strong year-over-year performanceFirst quarter 2022 reported and adjusted EPS* were $1.92 and $1.95, respectively, compared to first quarter 2021 reported and adjusted EPS of $(3.66) and $1.85, respectively The Company maintains its expectation for full year adjusted EPS of $6.85 to $7.45, which reflects the impact of higher than expected effective tax ratesWESTCHESTER, Ill., May 05, 2022 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported results for the first quarter of 2022. The results, reported in accordance with U.S. generally accepted accounting principles (“GAAP”) for 2022 and 2021, include items that are excluded from the non-GAAP financial...